Securities Code: 300529
Bond Code: 123117
Securities Abbreviation: Jianfan Bio-Medicine
Bond Abbreviation: Jianfan Convertible Bond
Announcement No.: 2026-048
Jianfan Bio-Medicine Technology Group Co., Ltd.
Announcement on the Acquisition of Equity in a Controlled Subsidiary from a Minority Shareholder and Related Party Transaction
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Jianfan Bio-Medicine Technology Group Co., Ltd. (hereinafter referred to as the "Company") held the third meeting of the Sixth Board of Directors on August 6, 2026. The meeting reviewed and approved the "Proposal on Acquiring Equity in a Controlled Subsidiary from a Minority Shareholder and Related Party Transaction." It was agreed to use the Company's own funds to acquire 37.60% of the equity of Aiduoduo Health Management (Guangdong Hengqin) Co., Ltd. (hereinafter referred to as "Aiduoduo") at a transfer price of RMB 17.592 million. The relevant situation is hereby announced as follows:
I. Transaction Overview
To further promote the Company's strategic development, enhance market expansion and business synergy capabilities, and improve the entire industrial chain layout of blood purification, thereby continuously strengthening core competitiveness, the Company will acquire 37.60% of Aiduoduo's equity using its own funds. This transaction uses the equity valuation determined by an appraisal firm with securities practitioner qualifications as the pricing reference, setting the transfer price for 37.60% of Aiduoduo's equity at RMB 17.592 million. After this equity acquisition, the Company will hold 100% of Aiduoduo's equity, and Aiduoduo will become a wholly-owned subsidiary of the Company.
Before this transaction, the Company held 62.40% of Aiduoduo's shares, and Zhuhai Zhongyan Technology Partnership (Limited Partnership) (hereinafter referred to as "Zhongyan Technology") held 37.60% of Aiduoduo's shares. Ms. Tang Xianmin, a director of the Company, is the executive partner of Zhongyan Technology. Therefore, in accordance with the relevant provisions of the "Shenzhen Stock Exchange GEM Stock Listing Rules," Zhongyan Technology is a related legal person of the Company, and this transaction constitutes a related party transaction.
On August 6, 2026, the Company held the third meeting of the Sixth Board of Directors, which reviewed and approved the "Proposal on Acquiring Equity in a Controlled Subsidiary from a Minority Shareholder and Related Party Transaction." Related director Ms. Tang Xianmin abstained from voting on this proposal. The above proposal has been reviewed and approved by the independent directors' special committee meeting of the Company. In accordance with the "Shenzhen Stock Exchange GEM Stock Listing Rules" and the "Articles of Association," this related party transaction does not need to be submitted to the Company's shareholders' meeting for deliberation.
This equity acquisition by the Company of a minority shareholder's equity in a controlled subsidiary and the related party transaction does not constitute a major asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies," and does not require approval from relevant departments.
II. Basic Information of the Related Party
(I) Zhuhai Zhongyan Technology Partnership (Limited Partnership)
-
Unified Social Credit Code: 91440400MA52AEBT8F
-
Enterprise Type: Limited Partnership Enterprise
-
Executive Partner: Tang Xianmin
-
Address: Room 105-58424, Building 6, Baohua Road, Hengqin New District, Zhuhai City (Centralized Office Area)
-
Registered Capital: RMB 21.592 million
-
Business Scope: Remote health management services; health food (pre-packaged) sales; human resource services (excluding occupational intermediary activities and labor dispatch services); sales of Class II medical devices.
-
Date of Establishment: September 25, 2018
-
Partner Structure: